Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Small Cell Lung Carcinoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Neoplasms 3Lung Neoplasms 3Triple Negative Breast Neoplasms 2Thymoma 2Squamous Cell Carcinoma of Head and Neck 2Mesothelioma, Malignant 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Thyroid Neoplasms 1Ovarian Neoplasms 1Non-squamous Non-small-cell Lung Cancer 1Neoplasm Metastasis 1NSCLC 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Advanced Non-squamous Non-small-cell Lung Cancer 1Advanced Non-small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

Pemetrexed 14Carboplatin 13osimertinib 11aflutinib 9Drug Therapy 9Gefitinib 8Radiotherapy 6Docetaxel 6Cisplatin 6pembrolizumab 5anlotinib 5Radiosurgery 5Paclitaxel 5icotinib 4Vinorelbine 4Gemcitabine 4Erlotinib Hydrochloride 4tislelizumab 3camrelizumab 3apatinib 3HM781-36B 3toripalimab 2spartalizumab 2rezivertinib 2dacomitinib 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NSCLC × lenvatinib × Thoracic × Clear all
NCT05078931 2025-07-30

A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

Shanghai Chest Hospital

Phase 2 Active not recruiting
35 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡